The FDA has accepted the biologics licensing application (BLA) resubmission for odronextamab, a potential treatment for ...

The FDA accepted odronextamab’s biologics license application resubmission for relapsed/refractory follicular lymphoma after ...

The company will push through with an accelerated approval application for odronextamab in follicular lymphoma, leaving ...

A year after the FDA rejected its marketing application for CD20xCD3 bispecific antibody odronextamab to treat two common ...

The patient remains NED for follicular lymphoma, with no recurrence detected in the latest CT scan. A declining immunoglobulin factor is noted, but it currently poses no health concerns. Stable lymph ...

FDA decision expected by July 30, 2025TARRYTOWN, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) ...

Lymphoma causes symptoms of organ failure before death. Learn what patients in palliative or hospice care could experience ...

A regulatory decision on odronextamab for R/R FL is expected by July 30, 2025. The Food and Drug Administration (FDA) has accepted for review the resubmitted Biologics License Application (BLA ...

The FDA will issue a decision on odronextamab’s accelerated approval in relapsed/refractory follicular lymphoma by 30 July ...

Follicular lymphoma is a diverse disease, both biologically and clinically. Patients may present with indolent, asymptomatic disease or more aggressive, symptomatic disease with high tumor burden.

Genmab (GMAB) announced that the Japan Ministry of Health, Labour and Welfare has approved EPKINLY or epcoritamab, for the treatment of ...

Beyond research, Germain concludes the conversation by providing helpful insights into the biggest challenges in lymphoma ...